Posted by Michael Wonder on 06 Feb 2018
GW Pharmaceuticals announces the EMA accepts Epidiolex (cannabidiol) marketing authorisation application for review
5 February 2018 - Application seeking regulatory approval of Epidiolex for seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
GW Pharmaceuticals announced today that the EMA has accepted for review the marketing authorisation application for Epidiolex (cannabidiol) for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
This acceptance follows submission of the application in December 2017.
